{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:02:41Z","timestamp":1789682561441,"version":"4.0.1"},"reference-count":167,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2023-00242186"],"award-info":[{"award-number":["RS-2023-00242186"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2025-25400013"],"award-info":[{"award-number":["RS-2025-25400013"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2025-16069638"],"award-info":[{"award-number":["RS-2025-16069638"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002644","name":"Pukyong National University Research Fund","doi-asserted-by":"publisher","award":["202411970001"],"award-info":[{"award-number":["202411970001"]}],"id":[{"id":"10.13039\/501100002644","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, characterized by a dense and immunosuppressive tumor microenvironment. With the limited actions of drugs and conventional monovalent antibodies, the success of existing cancer therapies is restricted so far. Recently, bispecific antibodies (BsAbs) have emerged as a promising therapeutic platform, capable of overcoming the limitations of current PDAC treatments by engaging T cells and delivering drugs to multiple targets in a selective manner. Furthermore, the recruitment of additional payloads expands their therapeutic potential, offering more selective drug delivery and presenting new possibilities for treating PDAC. However, a limited number of relevant studies and a lack of comprehensive research have hindered trials for the development of BsAbs and bispecific antibody-drug conjugates (BsADCs) in PDAC therapeutics. This review aims to provide the characteristics of BsAbs and BsADCs and their recent applications in PDAC treatment. Additionally, frequent targets of PDAC treatments will be discussed to suggest how to design BsAbs and BsADCs for PDAC treatments.<\/jats:p>","DOI":"10.3390\/biom15101477","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:27:29Z","timestamp":1760963249000},"page":"1477","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bispecific Antibody and Antibody-Drug Conjugate as Novel Candidates for Treating Pancreatic Ductal Adenocarcinoma"],"prefix":"10.3390","volume":"15","author":[{"given":"Hyeryeon","family":"Seo","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Pukyong National University, Busan 48513, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dabin","family":"Go","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Pukyong National University, Busan 48513, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Young","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Pukyong National University, Busan 48513, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinwoo","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Pukyong National University, Busan 48513, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Quy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Faculty of Chemical and Food Technology, University of Technology and Education, Ho Chi Minh City 75603, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0480-1804","authenticated-orcid":false,"given":"Minseok","family":"Kwak","sequence":"additional","affiliation":[{"name":"Department of Chemistry and Industry 4.0 Convergence Bionics Engineering, Pukyong National University, Busan 48513, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2479-0783","authenticated-orcid":false,"given":"Wooram","family":"Um","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Pukyong National University, Busan 48513, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-020-0363-5","article-title":"The tumour microenvironment in pancreatic cancer\u2014Clinical challenges and opportunities","volume":"17","author":"Ho","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Masugi, Y. (2022). The desmoplastic stroma of pancreatic cancer: Multilayered levels of heterogeneity, clinical significance, and therapeutic opportunities. Cancers, 14.","DOI":"10.3390\/cancers14133293"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","article-title":"Barriers and opportunities in pancreatic cancer immunotherapy","volume":"8","author":"Ju","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","article-title":"Translational advances in pancreatic ductal adenocarcinoma therapy","volume":"3","author":"Hosein","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Arias-Pinilla, G.A., and Modjtahedi, H. (2021). Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. Cancers, 13.","DOI":"10.3390\/cancers13081781"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40164-025-00624-9","article-title":"Development of a bispecific antibody\u2013drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors","volume":"14","author":"Luo","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Liu, C., Liu, D., Ji, Y., Sun, M., Gao, S., Ma, X., Zhong, D., Zhu, J., Cao, Y., and Qi, C. (2025). A bispecific antibody\u2013drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: A phase 1b trial. Nat. Med., In press.","DOI":"10.1038\/s41591-025-03792-7"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: A mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41698-024-00682-y","article-title":"Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression","volume":"8","author":"Henley","year":"2024","journal-title":"npj Precis. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1007\/s00417-024-06531-9","article-title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: From preclinical studies to phase 3 outcomes","volume":"262","author":"Agostini","year":"2024","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nbt1345","article-title":"Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin","volume":"25","author":"Wu","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: An emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104752","DOI":"10.1016\/j.critrevonc.2025.104752","article-title":"Recent development in bispecific antibody immunotherapy for hematological malignancies","volume":"212","author":"Han","year":"2025","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/jcpt.13741","article-title":"The pharmacology of blinatumomab: State of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials","volume":"47","author":"Mocquot","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/cpt.1396","article-title":"Bispecific Antibodies in the Treatment of Hematologic Malignancies","volume":"106","author":"Duell","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.4161\/mabs.28591","article-title":"A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells","volume":"6","author":"Reusch","year":"2014","journal-title":"MAbs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40259-025-00735-z","article-title":"Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline","volume":"39","author":"Shastri","year":"2025","journal-title":"BioDrugs"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: Natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12964-025-02270-4","article-title":"Nanobodies and their derivatives: Pioneering the future of cancer immunotherapy","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"Krupka","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2180794","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Bielski, P., Barczy\u0144ski, J., Mikitiuk, M., Myrcha, M., Ryka\u0142a, K., Boon, L., G\u0105sior, W., Hec-Ga\u0142\u0105zka, A., Holak, T.A., and Sitar, T. (2025). The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1486799"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.chembiol.2024.07.004","article-title":"Therapeutic potential of cis-targeting bispecific antibodies","volume":"31","author":"Oslund","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","article-title":"Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy","volume":"146","author":"Huang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann","year":"2012","journal-title":"MAbs"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results from the CHRYSALIS Phase 1 Study","volume":"39","author":"Luo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: Two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cheng, L.S., Zhu, M., Gao, Y., Liu, W.T., Yin, W., Zhou, P., Zhu, Z., Niu, L., Zeng, X., and Zhang, D. (2023). An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity. Cell. Mol. Biol. Lett., 28.","DOI":"10.1186\/s11658-023-00461-w"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12964-024-01562-5","article-title":"The enhanced antitumor activity of bispecific antibody targeting PD-1\/PD-L1 signaling","volume":"22","author":"Li","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Warwas, K.M., Meyer, M., Gon\u00e7alves, M., Moldenhauer, G., Bulbuc, N., Knabe, S., Luckner-Minden, C., Ziegelmeier, C., Heussel, C.P., and Z\u00f6rnig, I. (2021). Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.719116"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s12185-018-2545-9","article-title":"Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity","volume":"111","author":"Kitazawa","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Sindaco, P., Pandey, H., Isabelle, C., Chakravarti, N., Brammer, J.E., Porcu, P., and Mishra, A. (2023). The role of interleukin-15 in the development and treatment of hematological malignancies. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1141208"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40265-025-02155-3","article-title":"Zenocutuzumab: First Approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"ref_43","first-page":"298","article-title":"Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment","volume":"7","author":"Mbbs","year":"2025","journal-title":"Oncology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of zenocutuzumab in NRG1 fusion\u2013positive cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-024-01538-5","article-title":"Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma","volume":"17","author":"Long","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e012144","DOI":"10.1136\/jitc-2025-012144","article-title":"Anti-CTGF\/PD-1 bispecific antibody Y126S restrains desmoplastic and immunosuppressive microenvironment in pancreatic cancer","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1773201","DOI":"10.1080\/2162402X.2020.1773201","article-title":"Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients","volume":"9","author":"Lum","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_48","unstructured":"(2025, September 30). Phase Ib\/II Treatment of Advanced Pancreatic Cancer with Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs), Available online: https:\/\/clinicaltrials.gov\/study\/NCT03269526."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2967\/jnumed.120.259036","article-title":"Mesothelin\/CD3 Half-Life\u2013Extended Bispecific T-Cell Engager Molecule Shows Specific Tumor Uptake and Distributes to Mesothelin and CD3-Expressing Tissues","volume":"62","author":"Suurs","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_50","unstructured":"(2025, October 14). Phase 1a\/1b Study of CT-95 in Advanced Cancers Associated with Mesothelin Expression, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06756035."},{"key":"ref_51","unstructured":"United States Food and Drug Administration (2024, December 04). FDA Grants Accelerated Approval to Zenocutuzumab-Zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma Harboring NRG1 Gene Fusions, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5529","DOI":"10.7150\/thno.103372","article-title":"Bispecific Siglec-15\/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumors in vivo","volume":"15","author":"Shen","year":"2025","journal-title":"Theranostics"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., and Yi, M. (2023). Bispecific antibody targeting TGF-\u03b2 and PD-L1 for synergistic cancer immunotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1196970"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13046-023-02868-x","article-title":"Antibody drug conjugates: Hitting the mark in pancreatic cancer?","volume":"42","author":"Wittwer","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"S1456","DOI":"10.1016\/j.annonc.2024.10.158","article-title":"132MO Anti-claudin18. 2 (CLDN18. 2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC): Updated results from a phase I study","volume":"35","author":"Yu","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-024-01561-6","article-title":"Current and future immunotherapeutic approaches in pancreatic cancer treatment","volume":"17","author":"Farhangnia","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100849","DOI":"10.1016\/j.medj.2025.100849","article-title":"Antibody-drug conjugates: Current challenges and innovative solutions for precision cancer therapy","volume":"6","author":"Zhou","year":"2025","journal-title":"Med"},{"key":"ref_58","unstructured":"(2025, October 14). Phase 1 Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) with Expansion in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02672917."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"LB-B25","DOI":"10.1158\/1535-7163.TARG-17-LB-B25","article-title":"Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"A019","DOI":"10.1158\/1538-7445.PANCA22-A019","article-title":"Abstract A019: A multicenter randomized phase II study of gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel with a MUC5AC antibody (NPC-1C) in advanced pancreatic cancer previously treated with FOLFIRINOX (NCT01834235)","volume":"82","author":"Huffman","year":"2022","journal-title":"Cancer Res."},{"key":"ref_61","unstructured":"(2025, April 27). A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05458219."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1200\/JCO.2025.43.16_suppl.4017","article-title":"Claudin18.2 (CLDN18.2) expression and efficacy in pancreatic ductal adenocarcinoma (PDAC): Results from a phase I dose expansion cohort evaluating IBI343","volume":"43","author":"Yu","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_63","unstructured":"(2025, September 04). A Phase 1A\/B Study to Evaluate the Safety and Tolerability of EBC-129 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumours, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05701527."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1200\/JCO.2025.43.16_suppl.4018","article-title":"Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study","volume":"43","author":"Lentz","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_65","unstructured":"(2025, April 27). Phase 1 Dose-Escalation Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, as Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05547321."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1200\/JCO.2025.43.16_suppl.3028","article-title":"First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with pembrolizumab in patients with solid tumors","volume":"43","author":"Paisan","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"eadq0513","DOI":"10.1126\/sciadv.adq0513","article-title":"Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models","volume":"11","author":"Metrangolo","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/14712598.2022.2033204","article-title":"Clinical development of an anti-GPC-1 antibody for the treatment of cancer","volume":"22","author":"Ghosh","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1878-0261.12600","article-title":"TR1801-ADC: A highly potent cMet antibody\u2013drug conjugate with high activity in patient-derived xenograft models of solid tumors","volume":"14","author":"Gymnopoulos","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: Target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): Current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","article-title":"Antibody-drug conjugates and bispecific antibodies targeting cancers: Applications of click chemistry","volume":"46","author":"Hong","year":"2023","journal-title":"Arch. Pharm. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody\u2013drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Riccardi, F., Dal Bo, M., Macor, P., and Toffoli, G. (2023). A comprehensive overview on antibody-drug conjugates: From the conceptualization to cancer therapy. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1274088"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"ref_76","unstructured":"(2025, April 04). Study of XB002 in Subjects with Solid Tumors (JEWEL-101), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04925284."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"12071","DOI":"10.1002\/cam4.5893","article-title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer\/cholangiocarcinoma","volume":"12","author":"Lolkema","year":"2023","journal-title":"Cancer Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1200\/JCO.2022.40.16_suppl.4136","article-title":"Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208","volume":"40","author":"Spiliopoulou","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody\u2013Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00280-023-04507-w","article-title":"A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C","volume":"91","author":"Kim","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.drudis.2021.06.012","article-title":"Duocarmycin-based antibody\u2013drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress","volume":"26","author":"Yao","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_83","unstructured":"(2025, July 31). MGC018 with or Without MGA012 in Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03729596."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-21-0715","article-title":"Preclinical Development of ADCT-601, a Novel Pyrrolobenzodiazepine Dimer-based Antibody\u2013drug Conjugate Targeting AXL-expressing Cancers","volume":"21","author":"Zammarchi","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2792A","DOI":"10.1158\/1538-7445.AM2018-2792A","article-title":"Abstract 2792A: Preclinical activity of ADCT-601, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting AXL-expressing tumors","volume":"78","author":"Zammarchi","year":"2018","journal-title":"Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Valsasina, B., Orsini, P., Terenghi, C., and Ocana, A. (2024). Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents. Pharmaceuticals, 17.","DOI":"10.3390\/ph17101338"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","article-title":"Phase I\/II Trial of Labetuzumab Govitecan (Anti-CEACAM5\/SN-38 Antibody-Drug Conjugate) in Patients with Refractory or Relapsing Metastatic Colorectal Cancer","volume":"35","author":"Dotan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-0442","article-title":"Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody\u2013Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130)","volume":"17","author":"Sharkey","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results from the DESTINY-PanTumor02 Phase II Trial","volume":"42","author":"Makker","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: A key step in the development of antibody\u2013drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: Advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/s41587-022-01384-1","article-title":"Logic-gated antibody pairs that selectively act on cells co-expressing two antigens","volume":"40","author":"Oostindie","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_98","first-page":"3288","article-title":"The molecular mechanism underlying KRAS regulation on STK31 expression in Pancreatic ductal adenocarcinoma","volume":"115","author":"Chen","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Balamkundu, S., and Liu, C.-F. (2023). Lysosomal-cleavable peptide linkers in antibody\u2013drug conjugates. Biomedicines, 11.","DOI":"10.20944\/preprints202305.1084.v1"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: Is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1535-7163.MCT-16-0364","article-title":"Efficient payload delivery by a bispecific antibody\u2013drug conjugate targeting HER2 and CD63","volume":"15","author":"Vink","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_103","unstructured":"(2025, October 03). First in Human Study of AZD9592 in Solid Tumors (EGRET), Available online: https:\/\/clinicaltrials.gov\/study\/NCT05647122."},{"key":"ref_104","unstructured":"(2023, July 07). A Phase I Open Label First in Human Dose Escalation and Expansion Study of the Bispecific Anti-Mucin 1\u2014Epidermal Growth Factor Receptor Antibody Drug Conjugate M1231 as a Single Agent in Participants with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04695847."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1158\/1538-7445.AM2023-5737","article-title":"Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR\/c-MET targeted bispecific antibody drug conjugate","volume":"83","author":"McGrath","year":"2023","journal-title":"Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"TPS3156","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3156","article-title":"EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors","volume":"41","author":"Aggarwal","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Hsu, R., and Benjamin, D.J. (2023). A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1252652"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Hana, C., Thaw Dar, N.N., Galo Venegas, M., and Vulfovich, M. (2024). Claudins in cancer: A current and future therapeutic target. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25094634"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1538-7445.AM2022-5284","article-title":"Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression","volume":"82","author":"Knuehl","year":"2022","journal-title":"Cancer Res."},{"key":"ref_111","unstructured":"(2025, October 16). Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01), Available online: https:\/\/clinicaltrials.gov\/study\/NCT07100080."},{"key":"ref_112","unstructured":"(2025, June 29). PH-139: A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients with Advanced Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04827810."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2024-198370","article-title":"BVX001, a Bispecific ADC Targeting CD7-Positive AML with Favorable Toxicity Profile, Exhibits Significant Efficacy in Primary Patient Samples and PDX-Models","volume":"144","author":"Vitale","year":"2024","journal-title":"Blood"},{"key":"ref_114","unstructured":"Wahner, A. (2024, April 17). FDA Grants Orphan Drug Designation to BVX001 in AML. Available online: https:\/\/www.onclive.com\/view\/fda-grants-orphan-drug-designation-to-bvx001-in-aml."},{"key":"ref_115","unstructured":"Wang, W., Li, J., Guan, L., Xu, M., and Yin, Q. (2025, August 30). VBC103. Available online: https:\/\/www.adcreview.com\/drugmap\/vbc103\/."},{"key":"ref_116","unstructured":"AstraZeneca (2025, August 30). WCLC Advance Ambition: AstraZeneca Medicine for More than Half of All Patients Treated for Lung Cancer by 2030. Available online: https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/wclc-advance-ambition-astrazeneca-medicine-for-more-than-half-of-all-patients-treated-for-lung-cancer-2030.html."},{"key":"ref_117","unstructured":"(2025, January 29). A Dose Finding Study of ZW49 in Patients with HER2-Positive Cancers, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT03821233."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"B130","DOI":"10.1158\/1535-7163.TARG-23-B130","article-title":"Abstract B130: Phase 1 study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in patients with Human Epidermal Growth Factor 2 (HER2)-positive solid cancers","volume":"22","author":"Oh","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_119","unstructured":"(2025, March 11). Evaluation of JSKN016 Combination Therapy in Subjects with Advanced Non-Small Cell Lung Cancer: A Phase Ib Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06868732."},{"key":"ref_120","unstructured":"Alphamab Oncology (2025, August 30). Pipeline Programs: JSKN016. Available online: https:\/\/www.alphamabonc.com\/en\/pipeline\/jskn016.html."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"LB215","DOI":"10.1158\/1538-7445.AM2023-LB215","article-title":"Abstract LB215: A first-in-class anti-TROP2\/EGFR bispecific antibody-drug conjugate, DM001, exhibits potent anti-tumor efficacy","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res."},{"key":"ref_122","unstructured":"(2025, April 17). A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM001 in Patients with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06475937."},{"key":"ref_123","unstructured":"(2025, January 15). A Phase 1, Multicenter, Open-Label, First-in-Human, Dose Escalation and Expansion Study of DM005 in Patients with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06515990."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e15010","DOI":"10.1200\/JCO.2025.43.16_suppl.e15010","article-title":"DM005: An anti-EGFR\/c-MET bispecific antibody-drug conjugate for advanced solid tumors","volume":"43","author":"Wei","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_125","first-page":"A1","article-title":"1150 DM005, an EGFR \u00d7 MET bispecific antibody-drug conjugate, showed robust anti-tumor activity in PDX models","volume":"11","author":"Han","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_126","unstructured":"(2025, August 06). Evaluate BL-B01D1 in Patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05983432."},{"key":"ref_127","unstructured":"(2025, September 26). A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-B01D1 in Patients with Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05194982."},{"key":"ref_128","unstructured":"(2025, September 18). A Study of BL-B16D1 in Patients with Locally Advanced or Metastatic Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06475131."},{"key":"ref_129","unstructured":"(2025, October 14). A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BL-B16D1 in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06469008."},{"key":"ref_130","unstructured":"(2025, September 18). A Study of BL-B16D1 in Patients with Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06493864."},{"key":"ref_131","unstructured":"(2025, January 27). A Phase 1 Study of IBI3001 in Participants with Unresectable, Locally Advanced or Metastatic Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06349408."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"LB055","DOI":"10.1158\/1538-7445.AM2024-LB055","article-title":"Abstract LB055: IBI3001: A potentially first-in-class site-specifically conjugated B7-H3\/EGFR bispecific ADC for multiple solid tumors","volume":"84","author":"Guan","year":"2024","journal-title":"Cancer Res."},{"key":"ref_133","unstructured":"Institute, N.C. (2025, August 30). anti-B7-H3\/anti-EGFR Bispecific Antibody-Drug Conjugate IBI3001, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/anti-b7-h3-anti-egfr-bispecific-antibody-drug-conjugate-ibi3001."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"TPS8593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8593","article-title":"A phase 1\/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC","volume":"40","author":"Drilon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_135","unstructured":"(2025, February 28). A Phase 1\/2 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Patients with MET Overexpressing Advanced Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04982224."},{"key":"ref_136","unstructured":"(2019, July 18). A Phase 1\/2 Study of MEDI4276 in Adults Subjects with Select HER2-expressing Advanced Solid Tumors (MEDI4276), Available online: https:\/\/clinicaltrials.gov\/study\/NCT02576548."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","article-title":"First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody\u2013Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer","volume":"20","author":"Pegram","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_138","unstructured":"(2025, October 08). A Phase 1\/2 Study of GEN1286 in Patients with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06685068."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1538-7445.AM2024-6580","article-title":"Abstract 6580: A Novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models","volume":"84","author":"Xiao","year":"2024","journal-title":"Cancer Res."},{"key":"ref_140","unstructured":"(2025, August 22). Phase 1\/2A Open-Label Clinical Trial Evaluating Vbc101, an Egfr and Cmet Targeted BI-Specific Antibody Drug Conjugate, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07136779."},{"key":"ref_141","unstructured":"(2025, April 22). A Phase I, Multicentre, Open-Label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients with Advanced Solid Tumors. Available online: https:\/\/adisinsight.springer.com\/trials\/700379138."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"LB043","DOI":"10.1158\/1538-7445.AM2024-LB043","article-title":"Abstract LB043: VBC101-F11: An innovative EGFR\/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res."},{"key":"ref_143","unstructured":"(2025, August 28). A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1+ Axitinib Without or with Pembrolizumab (BL-B01D1+ Axitinib \u00b1 Pembrolizumab) in Patients with Locally Advanced or Metastatic Renal Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06962787."},{"key":"ref_144","unstructured":"(2025, September 23). A Randomized, Open-label, Multicenter, Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus TCbHP in Neoadjuvant Treatment of Breast Cancer with Positive HER2 Expression, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07043725."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2025.43.16_suppl.591","article-title":"Efficacy and safety of neoadjuvant TQB2102 in women with locally advanced or early HER2-positive breast cancer: A randomized, open-label, multi-centre phase 2 trial","volume":"43","author":"Li","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_146","unstructured":"(2024, December 31). A Randomized, Open-Label, Parallel-Controlled, Multi-center Phase III Study of JSKN003 Versus Investigator-Choice Chemotherapy for Platinum-Resistant, Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06751485."},{"key":"ref_147","unstructured":"(2025, March 24). A Randomized, Controlled, Open-Label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer Subjects, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06846437."},{"key":"ref_148","unstructured":"Oncology, A. (2025, August 30). Alphamab Oncology Presented Multiple Clinical Data of Anti-HER2 Biparatopic ADC JSKN003 at the 2025 ASCO Annual Meeting. Available online: https:\/\/www.prnewswire.com\/apac\/news-releases\/alphamab-oncology-presented-multiple-clinical-data-of-anti-her2-biparatopic-adc-jskn003-at-the-2025-asco-annual-meeting-302471380.html."},{"key":"ref_149","unstructured":"(2025, May 04). A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 with Chemotherapy of Physician\u2019s Choice in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure. Available online: https:\/\/adisinsight.springer.com\/trials\/700373045."},{"key":"ref_150","unstructured":"(2025, June 25). A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 with Chemotherapy of Physician\u2019s Choice in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06343948."},{"key":"ref_151","unstructured":"(2025, May 02). A Study Comparing BL-B01D1 with Chemotherapy of Physician\u2019s Choice in Patients with Recurrent or Metastatic Esophageal Squamous Cell Carcinoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06304974."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"LB214","DOI":"10.1158\/1538-7445.AM2023-LB214","article-title":"Abstract LB214: A first-in-class bispecific antibody-drug conjugate (DM002) targeting HER3 and the juxtamembrane domain of MUC1","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1158\/1538-7445.AM2024-2621","article-title":"Preclinical Efficacy of DM002, a bispecific HER3\u00d7 MUC1 antibody-drug conjugate with a novel DNA topoisomerase I inhibitor, in solid tumor models","volume":"84","author":"Zhang","year":"2024","journal-title":"Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1158\/1535-7163.MCT-15-0693","article-title":"Phase I study of DMOT4039A, an antibody\u2013drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer","volume":"15","author":"Weekes","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1126\/science.1171362","article-title":"Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer","volume":"324","author":"Olive","year":"2009","journal-title":"Science"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Qiu, S., Zhang, J., Wang, Z., Lan, H., Hou, J., Zhang, N., Wang, X., and Lu, H. (2023). Targeting Trop-2 in cancer: Recent research progress and clinical application. Biochim. Et Biophys. Acta (BBA)-Rev. Cancer, 1878.","DOI":"10.1016\/j.bbcan.2023.188902"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1158\/1078-0432.CCR-20-3210","article-title":"A MET Targeting antibody\u2013drug conjugate overcomes gemcitabine resistance in pancreatic cancer","volume":"27","author":"Cazes","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Schmiechen, Z.C., and Stromnes, I.M. (2021). Mechanisms governing immunotherapy resistance in pancreatic ductal adenocarcinoma. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.613815"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/nrgastro.2012.115","article-title":"The role of stroma in pancreatic cancer: Diagnostic and therapeutic implications","volume":"9","author":"Erkan","year":"2012","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/mco2.671","article-title":"Antibody\u2013drug conjugates in cancer therapy: Mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.2147\/DDDT.S135571","article-title":"Intracellular trafficking of new anticancer therapeutics: Antibody\u2013drug conjugates","volume":"11","author":"Kalim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2015.02.007","article-title":"Targeting FcRn for the modulation of antibody dynamics","volume":"67","author":"Ward","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: The neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1021\/acs.bioconjchem.9b00760","article-title":"A Comparative Study on Albumin-Binding Molecules for Targeted Tumor Delivery through Covalent and Noncovalent Approach","volume":"30","author":"Um","year":"2019","journal-title":"Bioconjugate Chem."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Park, A.-R., Jung, E.-Y., Shin, H.H., Park, J.-H., Lim, S.I., and Lee, D.-H. (2025). Single-chain variable fragments targeting domain II of human serum albumin for enhanced circulatory half-life via albumin association. Int. J. Biol. Macromol., 322.","DOI":"10.1016\/j.ijbiomac.2025.146933"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.actbio.2018.08.019","article-title":"Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration","volume":"79","author":"Son","year":"2018","journal-title":"Acta Biomater."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/10\/1477\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T04:38:29Z","timestamp":1761107909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/15\/10\/1477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":167,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biom15101477"],"URL":"https:\/\/doi.org\/10.3390\/biom15101477","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]}}}